(H1N1) became resistant to both oseltamivir and amantadine in a short span of 1 month. Oseltamivir-resistant A/Brisbane/59/2007-like clade 2B virus that had reassorted with A/Hong Kong/2652/2006-like clade 2C virus had apparently spread in the community and to other regions of the world. The possibility of reassortment with pandemic (H1N1) 2009 virus is a major concern. Resistance to oseltamivir of pandemic (H1N1) 2009 virus will compromise its use in treatment and render the billion-dose stockpile useless. Although the recently detected oseltamivir-resistant pandemic (H1N1) 2009 virus in Hong Kong was not a reassortant virus (4,5), we will continue to closely monitor antiviral drug resistance among circulating viruses, including pandemic (H1N1) 2009 virus and seasonal infl uenza virus A (H1N1), as well as infl uenza A (H3N2) viruses, to track how antiviral resistance evolves.
No takes yet. Share an insight, caveat, or question.
Pérez et al. (2009) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: